The bacteriophage community is experiencing a period of renaissance of funding and clinical breakthroughs, with 2023 having been a pivotal year when the UK government injected £210m to tackle global antimicrobial resistance.

With a highly promising possibility of bacteriophage therapy entering the market, the industry is on a run to enhance delivery strategies, phage-antibiotic synergies, and genome modifications. Following the latest clinical advancements from BiomX, the phage community is keen to witness outstanding results from the completion of patient dosing with their novel phage cocktail for the treatment of cystic fibrosis. Meanwhile, CRISPR-led innovation continues to redefine today’s approach to combating AMR, boosting the industry’s confidence in the application of engineered phage.